Vitruvian Partners Logo

Mid-Market Corporate Buyout Equity · Private Equity, VC & Investor

Vitruvian Partners

Private equity firm backing higher-growth companies across Europe and the US.

Available information varies by company and source.

Profile record updated:

Company facts

Official name
Vitruvian Partners LLP
Entity type
COMPANY
Founded
2006
Headquarters
United Kingdom
Company size
50–200
Market cluster / sector
Mid-Market Corporate Buyout Equity
Market role
Private Equity, VC & Investor
Official website
vitruvianpartners.com

What Vitruvian Partners does

Vitruvian Partners operates a fund-management model. It raises committed capital from limited partners into private equity funds, sources and executes investments in growth-stage and buyout opportunities, supports portfolio value creation, and monetises through recurring management fees on assets under management plus carried interest on realised investment gains.

Category differentiation

Vitruvian Partners is a private equity and growth capital investor, not an adtech, martech or software vendor. It manages investment funds rather than selling enterprise software or media inventory.

Strategic context

AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.

Vitruvian Partners LLP is a private equity investment firm headquartered in London. It raises capital into investment funds and deploys that capital into ambitious higher-growth companies through growth equity and buyout transactions. The firm serves institutional investors and other capital providers on the fund side, while backing portfolio companies with capital and strategic support on the operating side. The firm generates revenue primarily from fund management fees and performance-linked carried interest. The supplied evidence shows a multi-office footprint across London, Munich, Stockholm, Luxembourg and San Francisco, and the latest financial evidence states that Vitruvian funds have backed over 100 companies and have assets under management of approximately €20 billion.

Company news briefing

Briefing updated:

Vitruvian Partners has continued to expand its global growth portfolio through significant investments, including backing DeepIntent's launch of its AI-powered agentic advertising platform, Cora, for pharmaceutical marketers following a $637 million majority stake. Additionally, Vitruvian led a $600 million funding round in health insurance startup Angle Health at a $2.7 billion valuation and announced a strategic investment alongside TA Associates valuing German software vendor IGEL at over one billion euros. These developments highlight Vitruvian's ongoing strategy of backing high-growth technology and healthcare platforms.

Business model & monetisation

The firm monetises through private equity fund economics: recurring management fees charged on committed or managed capital, and carried interest earned as a share of profits on successful exits. Commercial value is created by fundraising, disciplined capital deployment, portfolio growth, and realisation events such as acquisitions or IPOs.

Fund management fees
Recurring fees on assets under management or committed capital
Carried interest
Performance-based share of realised investment profits
Co-investment and related fund economics
Investment-related participation alongside core funds

Products & capabilities

No products with linked sources are available in this view.

POLARIS7 WORKSPACE

Go deeper on Vitruvian Partners and its market context

Access extended corporate structures, historical M&A and partnership links, technical footprint data, and automated Watchlist briefings grounded in primary sources.

  • Corporate & subsidiary hierarchy
  • Competitor & partner network
  • Automated Watchlist briefings

Competitors & alternatives

Track competitor shifts

Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Vitruvian Partners's competitive landscape.

Monitor company

Subsidiaries & acquisitions

  • Healthcare-focused DSP and marketing cloud for pharmaceutical advertising.

View acquisition history

Recent recorded signals

Dates refer to the source publication. Older entries are historical context, not evidence of a new event.

  • IGEL Reaches Unicorn Status with Vitruvian Investment

    prnewswire.com

    M&A · Recorded impact score: 2/5

    IGEL, a German-based software vendor specializing in secure endpoint management, announced a strategic investment from Vitruvian Partners, a growth-focused international investment firm. This investment, alongside existing investor TA Associates, values IGEL at over one billion euros, granting it unicorn status. The funding will support IGEL's expansion in endpoint security, business continuity and disaster recovery (BC&DR), and operational technology (OT) solutions. IGEL reports over 40% growth in annual recurring revenue (ARR) in the past year. The transaction is expected to close in the first quarter of 2027, subject to regulatory approvals. William Blair served as financial advisor to TA and IGEL, while J.P. Morgan advised Vitruvian.

    • IGEL receives strategic investment from Vitruvian Partners, joining existing investor TA Associates.
    • The investment values IGEL at over one billion euros, achieving unicorn status.
  • Angle Health raises $600M at $2.7B valuation

    techcrunch.com

    Funding · Recorded impact score: 2/5

    Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.

    • Angle Health raised a $200 million Series C round.
    • The funding round included a $400 million tender offer.
  • DeepIntent launches agentic ad platform Cora for pharma marketing

    adweek.com

    Agentic Advertising · Recorded impact score: 4/5

    DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.

    • DeepIntent launched Cora, an agentic ad platform for pharma marketing.
    • Cora uses AI agents for campaign planning, audience targeting, and execution.

Explore company relationships

Questions about Vitruvian Partners

What is Vitruvian Partners?

Vitruvian Partners is a London-headquartered private equity firm that invests growth capital and buyout funding into higher-growth companies.

Who uses Vitruvian Partners?

Its direct customers are institutional investors and other limited partners that commit capital to its funds, while portfolio companies use the firm as a funding and strategic partner.

How does Vitruvian Partners make money?

It earns recurring management fees on funds and carried interest from profitable exits on portfolio investments.

Sources & coverage

This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.

3 publicly documented primary sources and citations linked across the market graph.

Start with a company or market. Track what changes.

Create your Polaris7 workspace to explore extended company profiles, organize relevant players into Watchlists, and receive focused briefings when material changes occur.